Sanofi Wins Crucial Tax Case In India Linked To Shantha Deal; Averts Charges Of Up To $170 Million
This article was originally published in PharmAsia News
Executive Summary
Sanofi’s deal for India’s Shantha Biotechnics was under the spotlight as India’s Income Tax department alleged that the deal was structured with an intention to avoid taxes. The decision may clear hurdles for other MNCs acquiring Indian companies.